Lilly says two of its experimental approaches to re-designing R&D are beginning to pay off. The first is called the "Mirror Portfolio" and involves funding external R&D through independent VC funds. The idea is to give Lilly access to innovation being developed on the outside. Its VC funds have now acquired two molecules for development - one for congestive heart failure and for bone healing in cancer.
The second new R&D approach is called Chorus - a small interdisciplinary drug development group within Lilly using a virtual model. The group focuses on development plans that progress compounds from candidate selection to proof of concept in human clinical trials. Chorus has been able to reach decisions 12 months earlier and at about half the former cost. The group has rendered decisions on 17 molecules with 6 resulting in positive proof of concept data. Lilly has now cloned the Chorus model in several other sites around the globe.
Posted by Bruce Lehr Feb 18th 2011.